Display again
SNCTP000001339 | NCT02467582

SAKK 41/13-Aspirin. Ergänzende Aspirin-Behandlung bei Dickdarmkrebs. Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase III Studie.

Data source: BASEC (Imported from 27.01.2022), WHO (Imported from 18.01.2022)
Changed: 20.12.2020
Disease category: Other Cancer

Brief description of trial (Data source: BASEC)

Die Studie untersucht bei Patienten mit operiertem Dickdarmkrebs und vorhandener PIK3CA-Mutation den Einfluss von Aspirin auf die Wahrscheinlichkeit eines Rückfalls der Tumorerkrankung. Etwa 17% der Patienten mit Dickdarmkrebs weisen eine solche Genmutation im Tumorgewebe auf. Das PIK3CA spielt eine wichtige Rolle beim Wachstum und Überleben der Krebszellen. Aspirin enthält den Wirkstoff Acetylsalicylsäure, welcher den Einfluss von PIK3CA auf die Krebszellen möglicherweise verändern kann. Um diesen Einfluss zu untersuchen, wird Aspirin gegenüber Placebo verglichen.

Health conditions investigated (Data source: BASEC)

Patienten mit operiertem Dickdarmkrebs

Health conditions (Data source: WHO)

Colon Cancer

Rare disease (Data source: BASEC)


Intervention investigated (e.g. drug, therapy or campaign) (Data source: BASEC)

Aspirin 100 mg oder Placebo werden täglich während 3 Jahren verabreicht

Interventions (Data source: WHO)

Drug: Aspirin;Drug: Placebo

Criteria for participation in trial (Data source: BASEC)

- Histologisch bewiesenes Kolonkarzinom.
- Stadium II (pT3/T4 N0 cM0) oder Stadium III (pTx pN+ cM0).
- Aktivierende PIK3CA Mutation in den Exon 9 oder 20.

Exclusion criteria (Data source: BASEC)

- Patienten mit Rektumkarzinom.
- Schwere und unkontrollierte kardiovaskuläre Erkrankung.

Inclusion/Exclusion Criteria (Data source: WHO)

Inclusion Criteria:

- Written informed consent according to ICH/GCP regulations before inclusion and prior
to any trial-related investigations.

- Histologically confirmed diagnosis of adenocarcinoma of the colon.

- Stage II (pT3/T4 N0 cM0) or stage III (pTx pN+ cM0) colon cancer.

- Availability of cancer tissue for central molecular testing.

- Presence of predefined, activating PIK3CA mutation in exons 9 or 20 (centrally

- Complete resection of the primary tumor (R0) within 14 weeks maximum before

- WHO performance status 0-2.

- Age between 18-80 years.

- Adequate hematological values: hemoglobin = 80 g/L, platelets = 50 x 109/L.

- Adequate hepatic function: total bilirubin =1.5xULN, AST =2.5xULN, ALT =2.5xULN, AP

- Calculated creatinine clearance > 30 mL/min, according to the formula of

- Women with child-bearing potential are using effective contraception, are not pregnant
or lactating and agree not to become pregnant during trial treatment. A negative
pregnancy test before inclusion (within 7 days) into the trial is required for all
women with child-bearing potential.

Exclusion Criteria:

- Previous or concomitant malignancy within 3 years of registration, except for
adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer.

- Multiple adenocarcinomas of the colon.

- Rectal cancer (defined as distance from anal verge to proximal/oral tumor edge =15

- Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or
IV, unstable angina pectoris, history of myocardial infarction) within three months
prior to registration.

- Systemic rheumatic diseases or degenerative disorders affecting the musculoskeletal
system with a relevant risk of requiring treatment with NSAIDs in the future.

- Comorbidities that require regular (i.e. more than 3x per month, any dose) intake of
acetylsalicylic acid or other NSAIDs or COX-2 inhibitors.

- Clinically relevant upper gastro-intestinal bleeding within 12 months prior to

- Presence of any bleeding disorder that is an absolute contraindication to the use of

- General tendency to hypersensitivity and history of asthma triggered by salicylates or
substances with a similar mechanism of action, and non-steroidal anti-inflammatory
drugs in particular

- Any serious underlying medical condition, at the judgment of the investigator, which
could impair the ability of the patient to participate in the trial (e.g. uncontrolled
infection, active autoimmune disease, uncontrolled diabetes).

- Concurrent treatment with other experimental drugs or treatment in an interventional
clinical trial within 30 days prior to trial entry. Concomitant use of adjuvant
chemotherapy for stage III and high risk stage II colon cancer according to
international treatment guidelines is allowed (chemotherapy regimens include
intravenous 5-fluorouracil or oral capecitabine either alone or in combination with
intravenous oxaliplatin).

- Psychiatric disorder precluding understanding of trial information, giving informed
consent or interfering with compliance for oral drug intake.

- Any familial, sociological or geographical condition potentially hampering proper
staging and compliance with the trial protocol.

- Known or suspected hypersensitivity to any component of the trial drug or any agent
given in association with this trial.

- Known galactose-1-phosphate uridyl transferase deficiency, UDP galactose 4 epimerase
deficiency, galactokinase deficiency, orFanconi-Bickel syndrome, congenital lactase
deficiency,or glucose-galactose malabsorption (due to the lactose-containing placebo).

- Any concomitant drugs contraindicated for use with the trial drug according to the
approved product information.

Further information on the trial in WHO primary registry


Further information on the trial from WHO database (ICTRP)


Further information on trial

Date trial registered


Incorporation of the first participant


Recruitment status


Academic title (Data source: WHO)

Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial

Type of trial (Data source: WHO)


Design of the trial (Data source: WHO)

Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).

Phase (Data source: WHO)

Phase 3

Primary end point (Data source: WHO)

Disease-free survival (DFS)

Secundary end point (Data source: WHO)

Adverse events (AEs);Cancer-specific survival (CSS);Overall survival (OS);Time to recurrence (TTR)

Contact information (Data source: WHO)

Please refer to primary and secondary sponsors

Trial results (Data source: WHO)

Results summary

no information available yet

Link to the results in the primary register

no information available yet

Information on the availability of individual participant data


Trial sites

Trial sites in Switzerland (Data source: BASEC)

Aarau, Baden, Basel, Bellinzona, Biel, Chur, Freiburg, Geneva, Lausanne, Liestal, Luzern, Olten, Sion, St. Gallen, Thun, Winterthur, Zurich

Countries (Data source: WHO)

Belgium, Germany, Hungary, Switzerland

Contact for further information on the trial

Details of contact in Switzerland (Data source: BASEC)

Rothgiesser Karin
031 508 41 57

Contact for general information (Data source: WHO)

Ulrich Güller, Prof;Karin Rotgiesser, PhD
Cantonal Hospital of St. Gallen
+41 31 389 91 91

Contact for scientific information (Data source: WHO)

Ulrich Güller, Prof;Karin Rotgiesser, PhD
Cantonal Hospital of St. Gallen
+41 31 389 91 91

Principal Sponsor/Investigator

Principal sponsor (Data source: WHO)

Swiss Group for Clinical Cancer Research

Additional sponsors (Data source: WHO)

European Organisation for Research and Treatment of Cancer - EORTC;Central European Society for Anticancer Drug Research

Authorisation by the ethics committee (Data source: BASEC)

Name of the authorising ethics committee (for multicentre studies only the lead committee)

Ethics Committee St. Gallen

Further trial identification numbers

Secondary ID (Data source: WHO)

SAKK 41/13 - Aspirin